bpc 157 for eczema BPC-157: The Body Protection Compound BPC-157 Therapy in Austin -

The publication reported body-weight and glycemic endpoints that were qualitatively consistent with REDEFINE 1, with the combination arm favored over placebo on the reported measures

Trial SURMOUNT-OSA (NEJM 2024) Population 469 adults with moderate-to-severe OSA + obesity

The letters EXP may follow the date

Based on available Phase 2 data, both agents share a side-effect profile broadly consistent with other medicines acting on metabolic hormone pathways, though the triple-agonist mechanism of retatrutide introduces some additional considerations

We are committed to offering our patients the most innovative and effective therapies to support their journey toward optimal health, vitality, and longevity